^
Association details:
Biomarker:MDM2 amplification
Cancer:Solid Tumor
Drug:milademetan (RAIN-32) (MDM2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Milademetan in Advanced/Metastatic Solid Tumors

Excerpt:
...- MDM2 amplification:...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Excerpt:
...- Participants with certain tumor types such as those with high prevalence of MDM2 amplification or overexpression (eg, well-differentiated [WD]/dedifferentiated [DD] liposarcoma) may be preferentially enrolled in Part 1....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma(WD/DD LPS), solid tumors (ST) and lymphomas (L).

Published date:
05/16/2018
Excerpt:
Objective responses and durable SD were seen in MDM2 amplified ST and DDLPS…
DOI:
10.1200/JCO.2018.36.15_suppl.11514
Trial ID: